News
Ensem Therapeutics doses first patient in phase 1/2 clinical study of ETX-636, a novel allosteric pan-mutant-selective PI3Ka inhibitor and degrader: Waltham, Massachusetts Saturda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback